DOCSLIB.ORG

Pdf 277.79 K

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pdf 277.79 K Iranian Journal of Pathology (2014) 9 (3), 167 - 180167 Review Article Plasmapheresis- Review Article Alireza Abdollahi 1,2 1. Dept. of Pathology, Tehran University of Medical Sciences, Tehran, Iran 2. Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran ABSTRACT Plasmapheresis, which is defined as the removal of plasma, can be either “adjusted plasma” or “exchange of plasma”. The former is defined as selective withdrawal of certain (un)-pathological plasma components in different ways such as perfusion and then returning the remained donor plasma to him, the latter is non-selective removal of all components of plasma to provide blood products for injection into patients or to be used as the input of blood transfusion refinery or to remove the pathogen contained plasma before compensating for the volume losses with an equal volume of plasma or more commonly, replacing plasma with a substitute fluid (colloid or crystalloid) such as albumin. Plasmapheresis was divided generally into two groups: 1- Plasma products by donor plasmapheresis 2- Therapeutic plasmapheresis Therapeutic plasma exchange or TPE are often attributed to plasma that exit from the body of patient then compensated by any kind of replacement fluid volumes to support neurmolemic situation of patients. Plasmapheresis is currently used as a therapeutic modality in a wide array of conditions. Generally, plasmapheresis is used when a substance in the plasma, such as immunoglobulin, is acutely toxic and can be efficiently removed. Myriad conditions fall under this category, including neurologic, hematologic, metabolic, dermatologic, rheumatologic, and renal diseases, as well as intoxications, that can be treated with plasmapheresis. Keywords: Plasmapheresis, Exchange the Plasma Address communications to: Dr Alireza Abdollahi, Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran. Email: [email protected] Vol.9 No.3, Summer 2014 IRANIAN JOURNAL OF PATHOLOGY 168 Plasmapheresis- Review Article Introduction rectly did plasmaphresis while preventing blood phaeresis is derived from a Greek word losses (3, 4). and it means removing or separating At the end of 1940s and early 1950s, simultane- (1). ously the appearance of plastic advanced blood A bag and advanced refrigerated centrifuge, he- Hemaphaeresis means bleeding from a donor and removing certain components and returning the maphresis was used more broadly as a treatment remaining components to him (2-3). method. In 1952, Carifols -Lucas used the man- There are two kinds of Hemaphaeresis (4): ual plasmapheresis procedure for the preparation 1- Cytapheresis is withdrawal of the whole blood of blood products. Thus, whole blood has been cells that have different titles by the type of cell. transfused from a donor, and then the plasma was If it is separated from leukocytes, it is known as separated from red blood cells by using centri- “Leukopheresis”, if separated from red blood fuge, and red blood cells after a week bleeding cells, it is “Erythropheresis” and if separated was returned to the donor (1, 8-10). He also re- from platelets it is as “Plateletpheresis” or ported the usefulness of pheresis in the patients` “Plasmapheresis”. therapy with hypertension disease. In 1950s, Dr. 2- Plasmapheresis, which is defined as the re- Edwin Cohn had established the using a continu- moval of plasma, can be either “adjusted plasma” ous flow centrifuge with more than 60 years since or “exchange of plasma”. The former is defined it was invented by De Laval for use in the dairy as selective withdrawal of certain (un)-patholog- industry to prepare blood products and improve ical plasma components in different ways such the effectiveness of a therapeutic plasmapheresis as perfusion and then returning the remained during the Second World War. These devices can donor plasma to him, the latter is non-selective be separated an on-line blood component in a removal of all components of plasma to provide closed system and in this system, the obtained blood products for injection into patients or to products were sterile (1, 11-13). be used as the input of blood transfusion refin- In 1962, Judson provided a device for separation ery or to remove the pathogen contained plasma of leukocytes from the whole blood by supporting before compensating for the volume losses with IBM and NCI and managed to produce 2,990 an equal volume of plasma or more commonly, units of IBM successfully. This device consists replacing plasma with a substitute fluid (colloid of disposable plastic tubes that were sterile or crystalloid) such as albumin (5-7). previously, and worked with a steady stream of closed system and it was the first device that History enables functionality to provide the processing Hendon (1902s) was the first to conduct research of large volumes of blood. This device is capable on the therapy method of Hemaphairesis by with- of exchanging plasma, collecting platelets, drawing blood from animals to be washed and granulocytes, lymphocytes and erythrocytes (1, reinjected. Fleig (1909) after Hendon used this 14-17). method for the treatment of human uremia (2). CS3000 were accessible commercially in Abel et al. (1914) have explained the removal of the early 1980s, produced by Fenwall. It is plasma technique through the treatment of poi- a continuous -flow device consisting of two soned dogs whose kidneys had been removed. To rotating chamber with a special form. In 1988, that effect, in a bid to get more anti-serum from Cobe Company began selling a new device as immunized horses for serum therapy, they cor- SPECTRA. This type of devices is automatically IRANIAN JOURNAL OF PATHOLOGY Vol.9 No.3, Summer 2014 Alireza Abdollahi, et al. 169 equipped with computer systems that can platelet donors during donor plasmapheresis and or the aphaeresis with minimal contamination of white loss volume will be compensated if it needed blood cell. Moreover, SPECTRA have been alternative and replacement fluids. Second, when moving for medical procedures affairs that are plasmapheresis has been done, simultaneously easily transferred to the patient’s room (18). donors have a long relaxation time that it was Subsequent development of the basic principles compared with the whole blood donors and established by the people, eventually leading to allows to refill the intervascular to the interstitial the construction of several kinds of semi-auto- capillaries with blood (24, 25-27). matic separation devices for clinical applications There are plasma hematoma and pain of needle in blood that the wider use of plasmaphresis was in the injection space of the body that is the most followed as a method of treatment. Continuation common complication in the donor plasma but of this trend depends on the development of con- the incidence of hematoma was not more than sumer devices and software whatever needs to be whole blood donors. more selective separation of blood components, There are rarely allergic reactions when it was and other ingredients can be returned to the do- prepared to rub the iodine fluid to skin. It was nor or patient (18, 19). an important adverse effect associated with Plasma pheresis was divided generally into two anticoagulant citrate when used as anticoagulant groups (1, 20): in vitro system and it was part of the remaining Plasma products by donor plasmapheresis blood components back to the donor’s Therapeutic plasma pheresis bloodstream. If donors have a low weight, maybe they have many symptoms of citrate (28-30). Plasma Products by Donor Plasmapheresis Sometimes there are rare mild reactions to citrate Description The donor plasmapheresis interpreted the donated (anesthesia around the mouth, tremor or tingling plasma by volunteers to be used in transfusion or sensation, tingling, or feeling cold or stuffy conversion to some specific products in plasma nose) and If the patients are faced with these processing center (21). reactions it is not alarming but demonstrated that doctors should control this process to reduce Complications of Donor Plasma and prevent serious symptoms of citrate toxicity. The donor plasma is far less than the whole donor Sometimes reactions have acute forms due to blood cell with the rate of adverse reactions in citrate toxicity (muscle cramps, whole body donors’ blood components (22-23). vibration, nausea, vomiting and tetanus) that are AFFP: apheresis fresh frozen plasma; 0.5% to rare in plasmapheresis but potentially have been 2.5%; a serious problem and disorder (31-33). Rare: < 0.5%; very rare: < 0.10%; Frequent: 5% to 20% Therapeutic PlasmaPheresis or Therapeutic Adverse reactions are more in first time donors Plasma Exchange (TPE) and it has less vasovagal responses (24). Description In contrary the whole blood donors, there Therapeutic plasma exchange or TPE are are two reasons to reduce the blood volume often attributed to plasma that exits from the (hypovolemia) that it has less reduction of body of patient then compensated by any blood volume than other donors in donors` kind of replacement fluid volumes to support plasmapheresis. First, an ejecting of the whole neurmolemic situation of patients (34). Table 1 blood volume is often less than whole blood shows Indications for Therapeutic Apheresis. Vol.9 No.3, Summer 2014 IRANIAN JOURNAL OF PATHOLOGY 170 Plasmapheresis- Review Article Table 1- Indications for therapeutic apheresis purified by a cheaper techniques such as hemofil- generally accepted for reimbursement by third- teration or unrecoverable high flux hem-dialysis. party payers (8,9) 2- Relatively removed material has a long half- life so that in vitro removal of such substances Plasma exchange into the body is passed much faster than the Ig*G clearing way of the body called as metabolism. Myasthenia gravis For example, the IgG with an approximately Eaton-Lambert syndrome Goodpasture syndrome 21 day’s half-life even if it has a treatment with Myeloma with renal failure immune-suppressors and stops producing new Guillain-Barre syndrome antibodies after 21 days, its decrease was at 50%.
Load more

Recommended publications
  • Fluid Resuscitation Therapy for Hemorrhagic Shock
    CLINICAL CARE Fluid Resuscitation Therapy for Hemorrhagic Shock Joseph R. Spaniol vides a review of the 4 types of shock, the 4 classes of Amanda R. Knight, BA hemorrhagic shock, and the latest research on resuscita- tive fluid. The 4 types of shock are categorized into dis- Jessica L. Zebley, MS, RN tributive, obstructive, cardiogenic, and hemorrhagic Dawn Anderson, MS, RN shock. Hemorrhagic shock has been categorized into 4 Janet D. Pierce, DSN, ARNP, CCRN classes, and based on these classes, appropriate treatment can be planned. Crystalloids, colloids, dopamine, and blood products are all considered resuscitative fluid treat- ment options. Each individual case requires various resus- ■ ABSTRACT citative actions with different fluids. Healthcare Hemorrhagic shock is a severe life-threatening emergency professionals who are knowledgeable of the information affecting all organ systems of the body by depriving tissue in this review would be better prepared for patients who of sufficient oxygen and nutrients by decreasing cardiac are admitted with hemorrhagic shock, thus providing output. This article is a short review of the different types optimal care. of shock, followed by information specifically referring to hemorrhagic shock. The American College of Surgeons ■ DISTRIBUTIVE SHOCK categorized shock into 4 classes: (1) distributive; (2) Distributive shock is composed of 3 separate categories obstructive; (3) cardiogenic; and (4) hemorrhagic. based on their clinical outcome. Distributive shock can be Similarly, the classes of hemorrhagic shock are grouped categorized into (1) septic; (2) anaphylactic; and (3) neu- by signs and symptoms, amount of blood loss, and the rogenic shock. type of fluid replacement. This updated review is helpful to trauma nurses in understanding the various clinical Septic shock aspects of shock and the current recommendations for In accordance with the American College of Chest fluid resuscitation therapy following hemorrhagic shock.
    [Show full text]
  • Intraoperative Fluid Therapy and Pulmonary Complications
    ■ Feature Article Intraoperative Fluid Therapy and Pulmonary Complications KRZYSZTOF SIEMIONOW, MD; JACEK CYWINSKI, MD; KRZYSZTOF KUSZA, MD, PHD; ISADOR LIEBERMAN, MD, MBA, FRCSC abstract Full article available online at ORTHOSuperSite.com. Search: 20120123-06 The purpose of this study was to evaluate the effects of intraoperative fl uid therapy on length of hospital stay and pulmonary complications in patients undergoing spine surgery. A total of 1307 patients were analyzed. Sixteen pulmonary complications were observed. Patients with a higher volume of administered crystalloids, colloids, and total intravenous fl uids were more likely to have postoperative respiratory com- plications: the odds of postoperative respiratory complications increased by 30% with an increase of 1000 mL of crystalloid administered. The best cutoff point for total fl uids was 4165 mL, with a sensitivity of 0.8125 and specifi city of 0.7171, for postoperative pulmonary complications. A direct correlation existed between fl uids and length of stay: patients who received Ͼ4165 mL of total fl uids had an average length of stay of 3.88Ϯ4.66 days vs 2.3Ϯ3.9 days for patients who received Ͻ4165 mL of total fl uids (PϽ.0001). This study should be considered as hypothesis-generating to design a prospective trial comparing high vs low intraoperative fl uid regiments for patients undergoing spine surgery. Dr Siemionow is from the Department of Orthopaedic Surgery, University of Illinois, Chicago, Illinois; Dr Cywinski is from the Department of Anesthesia, Cleveland Clinic, Cleveland, Ohio; Dr Kusza is from the Department of Anesthesia, Centrum Medyczne Bydgoszcz, Bydgoszcz, Poland; and Dr Lieberman is from Texas Back Institute, Plano, Texas.
    [Show full text]
  • Update on Volume Resuscitation Hypovolemia and Hemorrhage Distribution of Body Fluids Hemorrhage and Hypovolemia
    11/7/2015 HYPOVOLEMIA AND HEMORRHAGE • HUMAN CIRCULATORY SYSTEM OPERATES UPDATE ON VOLUME WITH A SMALL VOLUME AND A VERY EFFICIENT VOLUME RESPONSIVE PUMP. RESUSCITATION • HOWEVER THIS PUMP FAILS QUICKLY WITH VOLUME LOSS AND IT CAN BE FATAL WITH JUST 35 TO 40% LOSS OF BLOOD VOLUME. HEMORRHAGE AND DISTRIBUTION OF BODY FLUIDS HYPOVOLEMIA • TOTAL BODY FLUID ACCOUNTS FOR 60% OF LEAN BODY WT IN MALES AND 50% IN FEMALES. • BLOOD REPRESENTS ONLY 11-12 % OF TOTAL BODY FLUID. CLINICAL MANIFESTATIONS OF HYPOVOLEMIA • SUPINE TACHYCARDIA PR >100 BPM • SUPINE HYPOTENSION <95 MMHG • POSTURAL PULSE INCREMENT: INCREASE IN PR >30 BPM • POSTURAL HYPOTENSION: DECREASE IN SBP >20 MMHG • POSTURAL CHANGES ARE UNCOMMON WHEN BLOOD LOSS IS <630 ML. 1 11/7/2015 INFLUENCE OF ACUTE HEMORRHAGE AND FLUID RESUSCITATION ON BLOOD VOLUME AND HCT • COMPARED TO OTHERS, POSTURAL PULSE INCREMENT IS A SENSITIVE AND SPECIFIC MARKER OF ACUTE BLOOD LOSS. • CHANGES IN HEMATOCRIT SHOWS POOR CORRELATION WITH BLOOD VOL DEFICITS AS WITH ACUTE BLOOD LOSS THERE IS A PROPORTIONAL LOSS OF PLASMA AND ERYTHROCYTES. MARKERS FOR VOLUME CHEMICAL MARKERS OF RESUSCITATION HYPOVOLEMIA • CVP AND PCWP USED BUT EXPERIMENTAL STUDIES HAVE SHOWN A POOR CORRELATION BETWEEN CARDIAC FILLING PRESSURES AND VENTRICULAR EDV OR CIRCULATING BLOOD VOLUME. Classification System for Acute Blood Loss • MORTALITY RATE IN CRITICALLY ILL PATIENTS Class I: Loss of <15% Blood volume IS NOT ONLY RELATED TO THE INITIAL Compensated by transcapillary refill volume LACTATE LEVEL BUT ALSO THE RATE OF Resuscitation not necessary DECLINE IN LACTATE LEVELS AFTER THE TREATMENT IS INITIATED ( LACTATE CLEARANCE ). Class II: Loss of 15-30% blood volume Compensated by systemic vasoconstriction 2 11/7/2015 Classification System for Acute Blood FLUID CHALLENGES Loss Cont.
    [Show full text]
  • Fluid Resuscitation for Hemorrhagic Shock in Tactical Combat Casualty Care TCCC Guidelines Change 14-01 – 2 June 2014
    Fluid Resuscitation for Hemorrhagic Shock in Tactical Combat Casualty Care TCCC Guidelines Change 14-01 – 2 June 2014 Frank K. Butler, MD; John B. Holcomb, MD; Martin A. Schreiber, MD; Russ S. Kotwal, MD; Donald A. Jenkins, MD; Howard R. Champion, MD, FACS, FRCS; F. Bowling; Andrew P. Cap, MD; Joseph J. Dubose, MD; Warren C. Dorlac, MD; Gina R. Dorlac, MD; Norman E. McSwain, MD, FACS; Jeffrey W. Timby, MD; Lorne H. Blackbourne, MD; Zsolt T. Stockinger, MD; Geir Strandenes, MD; Richard B, Weiskopf, MD; Kirby R. Gross, MD; Jeffrey A. Bailey, MD ABSTRACT This report reviews the recent literature on fluid resusci- to hypotensive resuscitation, the use of DP, adverse ef- tation from hemorrhagic shock and considers the appli- fects resulting from the administration of both crystal- cability of this evidence for use in resuscitation of combat loids and colloids, prehospital resuscitation with thawed casualties in the prehospital Tactical Combat Casualty plasma and red blood cells (RBCs), resuscitation from Care (TCCC) environment. A number of changes to the combined hemorrhagic shock and traumatic brain in- TCCC Guidelines are incorporated: (1) dried plasma jury (TBI), balanced blood component therapy in DCR, (DP) is added as an option when other blood compo- the benefits of fresh whole blood (FWB) use, and re- nents or whole blood are not available; (2) the wording suscitation from hemorrhagic shock in animal models is clarified to emphasize that Hextend is a less desir- where the hemorrhage is definitively controlled prior to able option than whole blood, blood components, or resuscitation. DP and should be used only when these preferred op- tions are not available; (3) the use of blood products Additionally, recently published studies describe an in certain Tactical Field Care (TFC) settings where this increased use of blood products by coalition forces in option might be feasible (ships, mounted patrols) is dis- Afghanistan during Tactical Evacuation (TACEVAC) cussed; (4) 1:1:1 damage control resuscitation (DCR) Care and even in TFC.
    [Show full text]
  • Albumin Stewardship for Fluid Replacement in Plasmapheresis Kamarena Sankar, Pharm.D
    Albumin stewardship for fluid replacement in plasmapheresis Kamarena Sankar, Pharm.D. PGY-1 Resident Pharmacist Holmes Regional Medical Center Disclosure Statement .These individuals have nothing to disclose concerning possible financial or personal relationships with commercial entities (or their competitors) that may be referenced in this presentation: .Kamarena Sankar, Pharm.D. .Jay Pauly, Pharm.D. .Michael Sanchez, Pharm.D. Presentation Objective .Understand the post-implementation safety and cost data of an Albumin Stewardship Initiative for fluid replacement in plasmapheresis Background .Definition: Plasmapheresis is removal of a patient’s own plasma .Varies between patients .This also removes potentially harmful substances: .Immunoglobulin .Autoantibodies .Immune complexes .Monoclonal paraproteins .Protein-bound toxins Hollie M. Reeves Br J Haematol. 2014;164.3:342-351. Indications Guillain-Barré Syndrome, ANCA glomerulonephritis, Myasthenia Gravis, Autoimmune Encephalitis, Renal First-Line Transplantation, Thrombotic Thrombocytopenic Purpura (TTP) Cryoglobinemia, Familial Hypercholesterolemia, Second-Line Multiple Sclerosis Role Not Heparin-induced Thrombocytopenia (HIT), Nephrogenic Established Systemic Fibrosis Ineffective or Psoriasis, Dermatomyositis/Polymyositis Harmful J Schwartz. J Clin Apher. 2016;31.3:149-338. Background .Fluid Replacement during plasmapheresis: .Necessary to avoid hypotension .Institution practice: .Albumin 5% 3,000 mL .IV room processing time .Multiple manipulations .High cost J Schwartz. J Clin Apher. 2016;31.3:149-338. Background Literature .Yamada (2017) .Albumin in combination with normal saline .5:1, 4:1, 5:2, 1:1 .3 patients, 12 procedures .No blood pressure differences .Albumin only fluid replacement .Albumin-normal saline combination replacement .McCullough (1982) .Options for fluid replacement .Normal saline .Albumin Chisa Yamada. J Clin Apher. 2017;32.1:5-11. J McCullough. Vox Sang.
    [Show full text]
  • 6 Alternatives to Allogeneic Blood Transfusions
    Best Practice & Research Clinical Anaesthesiology Vol. 21, No. 2, pp. 221–239, 2007 doi:10.1016/j.bpa.2007.02.004 available online at http://www.sciencedirect.com 6 Alternatives to allogeneic blood transfusions Andreas Pape* Dr. med. Clinic of Anaesthesiology, Intensive Care Medicine and Pain Management, J. W. Goethe University Hospital Frankfurt am Main, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany Oliver Habler Professor Dr. med. Department Head Clinic of Anaesthesiology, Surgical Intensive Care Medicine and Pain Management, Nordwest-Krankenhaus, Steinbacher Hohl 2-26, 60488 Frankfurt am Main Germany Inherent risks and increasing costs of allogeneic transfusions underline the socioeconomic rel- evance of safe and effective alternatives to banked blood. The safety limits of a restrictive trans- fusion policy are given by a patient’s individual tolerance of acute normovolaemic anaemia. Iatrogenic attempts to increase tolerance of anaemia are helpful in avoiding premature blood transfusions while at the same time maintaining adequate tissue oxygenation. Autologous trans- fusion techniques include preoperative autologous blood donation (PAD), acute normovolaemic haemodilution (ANH), and intraoperative cell salvage (ICS). The efficacy of PAD and ANH can be augmented by supplemental iron and/or erythropoietin. PAD is only cost-effective when based on a meticulous donation/transfusion plan calculated for the individual patient, and still carries the risk of mistransfusion (clerical error). In contrast, ANH has almost no risks and is more cost-effective. A significant reduction in allogeneic blood transfusions can also be achieved by ICS. Currently, some controversy regarding contraindications of ICS needs to be resolved. Artificial oxygen carriers based on perfluorocarbon (PFC) or haemoglobin (haemoglobin-based oxygen carriers, HBOCs) are attractive alternatives to allogeneic red blood cells.
    [Show full text]
  • Review of Fluid Therapy in Acute Blood Loss
    HOW-TO SESSION: FIELD ANESTHESIA AND PAIN MANAGEMENT Review of Fluid Therapy in Acute Blood Loss Michele L. Frazer, DVM, Diplomate ACVIM, ACVECC Permissive hypotension and increased use of plasma and fresh, warm, whole blood instead of crystalloid fluids may benefit equine patients with acute blood loss. Author’s address: Hagyard Equine Medical Institute, 4250 Iron Works Pike, Lexington, KY 40511; e-mail: [email protected]. © 2013 AAEP. 1. Introduction This eventually leads to organ dysfunction and car- Acute blood loss in the veterinary patient is an diovascular collapse. emergency that many practitioners must manage in Patients with blood loss can be placed into one of the field or hospital setting. Diagnosis may be ob- four categories as defined by the American College of 1 vious in cases of external blood loss, whereas inter- Surgeons. Category 1 is loss of Յ15% of blood nal blood loss may be more difficult to determine. volume. Transcapillary refill typically compen- Acute hemorrhage can occur into the peritoneal, sates for this loss and maintains blood volume and pleural, or pericardial cavities; reproductive tract; blood pressure. Category 2 is loss of 15% to 30% of gastrointestinal tract; guttural pouches; joints; and blood volume. Compensatory mechanisms such as muscle tissue. In the equine patient, common tachycardia and tachypnea occur, and sympathetic causes include trauma, rupture of a vessel in the vasoconstriction can typically maintain blood pres- reproductive tract in pre- or post-foaling mares, frac- sure. Category 3 is loss of 30% to 40% of blood tured ribs in foals, and inadequate hemostasis volume. Compensatory mechanisms can no longer during surgery.
    [Show full text]
  • Intraoperative Fluids: How Much Is Too Much?
    British Journal of Anaesthesia 109 (1): 69–79 (2012) Advance Access publication 1 June 2012 . doi:10.1093/bja/aes171 Intraoperative fluids: how much is too much? M. Doherty1* and D. J. Buggy1,2 1 Department of Anaesthesia, Mater Misericordiae University Hospital, University College Dublin, Ireland 2 Outcomes Research Consortium, Cleveland Clinic, OH, USA * Corresponding author. E-mail: [email protected] Downloaded from Summary. There is increasing evidence that intraoperative fluid therapy Editor’s key points decisions may influence postoperative outcomes. In the past, patients undergoing major surgery were often administered large volumes of † Both too little and excessive fluid http://bja.oxfordjournals.org/ during the intraoperative period can crystalloid, based on a presumption of preoperative dehydration and adversely affect patient outcome. nebulous intraoperative ‘third space’ fluid loss. However, positive perioperative fluid balance, with postoperative fluid-based weight gain, is associated with † Greater understanding of fluid increased major morbidity. The concept of ‘third space’ fluid loss has been kinetics at the endothelial glycocalyx emphatically refuted, and preoperative dehydration has been almost enhances insight into bodily fluid eliminated by reduced fasting times and use of oral fluids up to 2 h before distribution. operation. A ‘restrictive’ intraoperative fluid regimen, avoiding hypovolaemia † Evidence is mounting that fluid but limiting infusion to the minimum necessary, initially reduced major at Fundação Coordenação de Aperfeiçoamento Pessoal Nível Superior on September 12, 2012 therapy guided by flow based complications after complex surgery, but inconsistencies in defining restrictive haemodynamic monitors improve vs liberal fluid regimens, the type of fluid infused, and in definitions of perioperative outcome.
    [Show full text]
  • Blood Group Have Increased Susceptibility to Symptomatic \(Vibrio\) \(Cholerae\) O1 Infection
    Individuals with Le(a+b−) Blood Group have Increased Susceptibility to Symptomatic \(Vibrio\) \(cholerae\) O1 Infection The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Arifuzzaman, Mohammad, Tanvir Ahmed, Mohammad Arif Rahman, Fahima Chowdhury, Rasheduzzaman Rashu, Ashraful I. Khan, Regina C. LaRocque, et al. 2011. Individuals with Le(a+b−) blood group have increased susceptibility to symptomatic \(Vibrio\) \(cholerae\) O1 infection. PLoS Neglected Tropical Diseases 5(12): e1413. Published Version doi:10.1371/journal.pntd.0001413 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:9369412 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Individuals with Le(a+b2) Blood Group Have Increased Susceptibility to Symptomatic Vibrio cholerae O1 Infection Mohammad Arifuzzaman1,2, Tanvir Ahmed1, Mohammad Arif Rahman1, Fahima Chowdhury1, Rasheduzzaman Rashu1, Ashraful I. Khan1, Regina C. LaRocque2,3, Jason B. Harris2,4, Taufiqur Rahman Bhuiyan1, Edward T. Ryan2,3,5, Stephen B. Calderwood2,3,6., Firdausi Qadri1*. 1 Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research Bangladesh (ICDDR,B), Dhaka, Bangladesh, 2 Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America,
    [Show full text]
  • DENGUE CASE MANAGEMENT Live In/Travel to Dengue Endemic Area
    PRESUMPTIVE DIAGNOSIS DENGUE CASE MANAGEMENT Live in/travel to dengue endemic area. Fever and two of the following criteria: • Anorexia and nausea • Rash • Aches and pains • Warning signs • Leukopenia WARNING SIGNS* • Tourniquet test positive • Abdominal pain or tenderness • Persistent vomiting Laboratory confirmed dengue • Clinical fluid accumulation ASSESSMENT (important when no sign of plasma leakage) • Mucosal bleed • Lethargy, restlessness • Liver enlargment >2 cm • Laboratory: increase in HCT concurrent with rapid decrease in platelet count *(requiring strict observation and medical intervention) NEGATIVE Co-existing conditions POSITIVE Social circumstances NEGATIVE DENGUE WITHOUT WARNING SIGNS DENGUE WITH WARNING SIGNS CLASSIFICATION Group A Group B Group C (May be sent home) (Referred for in-hospital care) (Require emergency treatment) Group criteria Group criteria OR: Existing warning signs Group criteria Patients who do not have warning signs Patients with any of the following features: Patients with any of the following features: AND • co-existing conditions such as Laboratory tests • severe plasma leakage with shock and/or fluid accumulation with respiratory distress who are able: pregnancy, infancy, old age, diabetes • full blood count (FBC) • severe bleeding • to tolerate adequate volumes of oral mellitus, renal failure • haematocrit (HCT) • severe organ impairment fluids • social circumstances such as living • to pass urine at least once every alone, living far from hospital Treatment Laboratory tests 6 hours Obtain reference HCT before fluid therapy. • full blood count (FBC) Laboratory tests Give isotonic solutions such as 0.9 % saline, • haematocrit (HCT) Laboratory tests • full blood count (FBC) Ringer’s Lactate. Start with 5–7 ml/kg/hr for • other organ function tests as indicated • full blood count (FBC) • haematocrit (HCT) 1–2 hours, then reduce to 3–5 ml/kg/hr for Treatment of compensated shock • haematocrit (HCT) 2–4 hr, and then reduce to 2–3 ml/kg/hr Treatment or less according to clinical response.
    [Show full text]
  • 181121 Selecting Iv Fluids to Manage Fluid Loss in Critically Ill Patients
    Copyright EMAP Publishing 2018 This article is not for distribution except for journal club use Clinical Practice Keywords Crystalloid/Colloid/Blood products/Osmolarity Review This article has been Fluid therapy double-blind peer reviewed In this article... ● Causes of insensitive and sensitive fluid loss in critically ill patients ● Different types of intravenous fluids, their indications and side-effects ● Guidance on the treatment of fluid loss and fluid resuscitation algorithm Selecting IV fluids to manage fluid loss in critically ill patients Key points Authors Xabi Cathala is a lecturer in vocational learning, Institute of Vocational Intravenous fluid Learning; Calvin R Moorley is an associate professor in adult nursing, Faculty of therapy is one of Health and Social Care; both at London South Bank University. the most common treatments in Abstract Critically ill patients admitted to intensive care settings may need to be intensive care administered intravenous fluids – for example, to restore their blood pressure or replace lost blood. A crucial question arising in the management of these patients Fluid loss leads to is which type of fluid to use. To decide which fluid is most appropriate and safest, hypovolaemia and, nurses working in critical care need to understand how the different types of fluids if left untreated, act on the human body. This article describes the three main types of fluids to death (crystalloids, colloids and blood products), their composition, mode of action, indications and side-effects. Crystalloids vary in their osmolarity Citation Cathala X, Moorley C (2018) Selecting IV fluids to manage fluid loss in and so have critically ill patients Nursing Times [online]; 114: 12, 41-44.
    [Show full text]
  • Introduction: Therapeutic Apheresis Effects on Medications
    Introduction: Therapeutic apheresis effects on medications AABB/ASFA Joint Session Suzanne Thibodeaux, MD PhD Assistant Professor Department of Pathology and Immunology Washington University in St. Louis October 14, 2018 Financial disclosures None www.aabb.org 2 Learning objectives By the end of the talk, the audience should be able to: 1. Describe the basic principles of therapeutic apheresis 2. Identify apheresis attributes that may affect medication levels 3. Identify patient attributes that may affect medication levels www.aabb.org 3 www.aabb.org 4 https://www.google.com/search?q=apheresis&ie=utf-8&oe=utf-8&client=firefox-b-1-ab What is apheresis? According to the American Society for Apheresis A procedure in which blood of the patient or donor is passed through a medical device which separates one or more components of blood and returns the remainder with or without extracorporeal treatment or replacement of the separated component. 5 Schwartz, et al. Journal of Clinical Apheresis 31:149–162 (2016) Where did apheresis come from? Cream separators and computer companies! 1870s 1940s-1950s 1960s Cream separator - hand-cranked WW2 – isolation of serum albumin IBM –development of automated continuous centrifugation fraction from plasma, other apheresis, IBM 2990 separation of blood components Dr. Karl de Laval Dr. Edwin Cohn George Judson http://worldapheresis.org/wp-content/uploads/2015/07/CDLposter.png; https://www-03.ibm.com/ibm/history/exhibits/healthcare/healthcare_08.html The apheresis circuit is continuous Adapted from: Williams
    [Show full text]